Frontier Knowledge and Novel Therapeutic Modalities for Rhinologic Disease
Our conceptual understanding of inflammation continues to evolve as we discover new mechanisms. In the setting of chronic inflammation such as that seen in chronic rhinosinusitis (CRS), the challenge arises in discerning whether these mechanisms constitute a physiological or pathological immune response necessitating novel intervention. The enormous heterogeneity and complexity of the human immune system, CRS patient diversity, and environmental influences necessitates interinstitution data sharing to better understand pathologies causing clinical disease and translation to effective therapy. For patients requiring surgical treatment, there are nuances in surgical techniques and perioperative care that influence surgical outcomes, patient satisfaction, and clinical practice. Such complex issues are covered elegantly in this journal. Through a rigorous selection process, the American Journal of Rhinology and Allergy (AJRA) also brings the latest developments in basic science and clinical research from international authors to interest a broad readership, including otolaryngologists, immunologists, and scientists.
The July 2018 issue of AJRA invites readers to think outside-the-box regarding the nervous system and inflammation. Historically, the immune system and nervous systems are considered separate fields of study. However, in recent years, neuroimmune interactions are recognized as an important contributor to inflammation. 1 In this issue, 2 exciting pilot studies form the basis for exploring neurogenic control of inflammation and of ciliary function, which may behold vital therapeutic potential in the subgroups of CRS patients. Wu et al. discover a reduction in the axonal guidance and neuronal growth associated proteins in nasal polyps compared with control tissue which correlated with objective measures of severe clinical disease and allergic inflammation. 2 The study by Do et al. further exemplifies the role of the nervous system, in particular neuropeptides, in airway defense and immune function by influencing ciliary function. 3 This research group investigates the molecular basis for acetylcholine-induced ciliary beat frequency and highlights the diverse and complex control of this vital component of airway defense mechanism.
Another cell type to take center stage in inflammation is the fibroblast. Stromal cells are no longer considered innocent bystanders, but rather play an active role in chronic inflammation. Shin et al. investigate the role of Methyl-CpG-binding protein 2 (MeCP2), which is a transcriptional regulator, in transforming growth factor (TGF)-b1-induced myofibroblast differentiation and extracellular matrix production in nasal polyp-derived fibroblasts. 4 Higher levels of MeCP2 were found in nasal polyps compared with control tissue. Blocking MeCP2 activity demonstrated a significant reduction in TGFB-1 stimulated collagen expression, adding another potential avenue to curtail CRS inflammation.
In any ailment, an accurate diagnosis is fundamental to effective therapy. This issue reiterates the challenges in defining, diagnosing, and treating IgE-mediated allergic inflammation. The study by Wanjun et al. exemplifies the clinical relevance of end organ-based diagnosis. 5 They demonstrated that allergen nasal provocation test results correlated with rhinitis symptoms better than serum specific IgE or skin prick test wheal size. In line with this observation, Saricilar et al. investigate the diagnostic value of nasal brushings to determine total and specific IgE levels in rhinitis patients. They envisage this to be especially helpful in determining local IgEmediated allergic responses in individuals where systemic markers of atopy are absent. 6 In pursuit of early diagnosis for eosinophilic CRS (eCRS), Ho et al. delve into a number of potential systemic biomarkers. 7 eCRS is associated with worse clinical prognosis to non-eCRS patients. This group's findings corroborate the value of elevated peripheral blood eosinophil levels and the ratio of eosinophil to total white cell count in predicting tissue eosinophilia in a large cohort study. This is a step toward identifying eCRS early, before surgical intervention, to guide patient treatment and prognosis.
As surgeons, we strive to achieve the best results for our patients, through reflection on and critical evaluation of treatments and surgical techniques on clinical outcomes, patient experience, and patient satisfaction. This issue of AJRA explores some of these treatments in depth. Bevacizumab is a recombinant, humanized monoclonal antibody to vascular endothelial growth factor used to treat hereditary hemorrhagic telangiectasia. Halderman et al. undertake an evidence-based review of the methods of drug delivery (topical, submucosal injection, and intravenous) and their efficacy in managing the frequency and severity of epistaxis. 8 Saline nasal irrigation is fundamental in the treatment for rhinitis and CRS patients, aimed at improving ciliary function, yet is fraught with much controversy regarding the optimum formulation. Laboratory studies show better mucus rheological properties with hypertonic saline preparations; however, clinical studies show conflicting results. Notwithstanding the limitations of meta-analyses, Kanjanawasee et al. analyze the clinical benefits of hypertonic and isotonic saline treatments in CRS and rhinitis patients to help treating physicians make an informed clinical recommendation for their patient. 9 In another article, Walters et al. document the long-term safety, tolerability, and benefits of aspirin desensitization and continuous daily aspirin therapy for greater than 10 years in CRS patients with aspirinexacerbated respiratory disease. 10 For patients with refractory frontal sinusitis undergoing endoscopic Draf 3 surgery, frontal neo-ostium stenosis is a significant problem and is influenced by anatomical, surgical, and inflammatory factors. In this issue, Zhang et al. highlight the importance of the anterior-posterior diameter of the frontal neo-ostium and eosinophil levels in predicting ostial restenosis.
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These preoperative predictive factors would be helpful when counseling patients and may promote innovation in surgical and medical measures to improve clinical outcomes.
Over the last few years, some otolaryngologists have adopted balloon sinus dilation into their interventional armamentarium for CRS. Stolovitzky et al. prospectively document their 12-month outcomes from an observational study in CRS patients with the addition of balloon sinus dilation compared with medical management alone. 12 Endoscopic dacryocystorhinostomy (DCR) is successful in treating sac and postsac obstruction of the nasolacrimal system. Stenting postprocedure for a variable period of time (4-12 weeks) is a common practice, and Ci ger et al. share their experience and clinical outcomes of endoscopic DCR without stenting and without mucosal flaps. 13 Successful endoscopic repair of cerebrospinal fluid leaks is the cornerstone for pushing the surgical frontier in endoscopic sinus and skull base surgery. Lam et al. impart their institution's experience with autologous fat as a sole grafting material or as part of multilayered reconstruction with discussion of specific patient scenarios to illustrate salient clinical points. 14 Patient preferences, comorbidities, cost of intervention, and changes in health-care infrastructure are also driving innovation and change in surgical practice. In some centers, there is a shift toward office-based procedures. Endoscopic sinus surgery performed safely and effectively under local anesthesia is described in the manuscript by Scott et al., along with especially helpful illustrations for techniques of local anesthesia. 15 Other authors call for further evaluation and standardization of treatments so that safe and effective care can be maintained within a sustainable health-care system. Arianpour et al. shed light on the role the sinus surgeon plays in the opioid prescribing patterns for patients undergoing sinus surgery, 16 and Tabaee et al. describe the billing patterns for nasal endoscopy among the members of the American Rhinologic Society. 17 These important aspects of clinical practice have relevance to surgeons beyond the borders of North America.
I commend the editors and reviewers of this journal on their efforts in keeping this issue of AJRA on track to inform its readers on the latest translational, clinical, technical, and socioeconomic aspects of current surgical practice. It is this data that helps shape day-to-day clinical practice at an individual, institutional, national, and international level and fuels clinical curiosity to drive further cutting edge research. The editorial board and I hope the contents of this issue brings refreshing perspectives to your understanding of rhinologic disease and are helpful to your practice.
